AddedRisk Factors
Controlled substances as defined in the CSA are subject to a number of requirements and restrictions under the CSA and implementing regulations, including certain registration, security, recordkeeping, reporting, import, export, prescription, distribution and other requirements administered by the DEA. Individual states have also established controlled substance laws and regulations. FDA-approved products such as LUMRYZ, which contain sodium oxybate (a Schedule I controlled substance) as their API, are deemed to be Schedule III controlled substances under the CSA. Although state-controlled substances laws often mirror federal law, various states may also separately schedule LUMRYZ. We or the third-parties with which we work to develop, manufacture and/or commercialize controlled substances such as LUMRYZ may be required to obtain separate state registrations, permits or licenses in order to be able to manufacture, research, distribute, import, export, administer or prescribe such controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
U.S. facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing of controlled substances such as LUMRYZ must be registered and/or licensed to perform these activities and must comply with the security, control, recordkeeping and reporting obligations under the CSA, DEA regulations and corresponding state requirements. DEA and state regulatory bodies conduct periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining necessary registrations and quotas and complying with the regulatory obligations may result in delays in the development, manufacture and commercialization of LUMRYZ and future product candidates or products that may contain controlled substances. Furthermore, failure to maintain compliance with the CSA and DEA and state regulations by us or any of contractors, distributors or pharmacies with which we work can result in regulatory action that could materially adversely effect our business, financial condition, cash flows and results of operations. In addition, if we change any third-party upon whom we rely to conduct our research, manufacturing, distributing, importing, exporting, or dispensing activities, doing so will result in additional costs and expenses and may take a significant amount of time, and we may be unsuccessful in identifying a new, satisfactory third-party, any of which could materially and adversely affect our business, financial condition, and results of operations. DEA and state regulatory bodies may seek civil penalties, refuse to renew necessary registrations or licenses, or initiate proceedings to restrict, suspend or revoke those registrations or licenses. In certain circumstances, violations could lead to criminal penalties.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We and the third parties that manufacture LUMRYZ in the U.S. are subject to the DEA’s annual manufacturing and procurement quota requirements. The annual quota allocated to us or our U.S. manufacturing partners for sodium oxybate may not be sufficient to meet commercial demand of LUMRYZ. Consequently, any delay or refusal by the DEA in establishing our, or U.S. manufacturing partners’, procurement and/or production quotas for controlled substances could delay or stop our commercial activities and future development/clinical activities, which could materially adversely effect our business, financial condition, cash flows and results of operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
In April 2025, Mural announced its intent to discontinue all clinical development of nemvaleukin alfa following a review of clinical trial data, reduce its workforce by approximately 90% and commence the exploration of strategic alternatives focused on maximizing shareholder value. In August 2025, Mural and XOMA Royalty Corporation announced a definitive agreement for XOMA Royalty’s wholly owned subsidiary to acquire all issued and to be issued share capital of Mural, which was completed in December 2025. We do not believe that these events will adversely affect the tax treatment of the separation; however, the IRS or the courts may challenge this position and should any such challenge prevail, we and/or our shareholders that are subject to U.S. federal income tax could incur significant tax liabilities.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
VUMERITY and other products using our NanoCrystal or OCR technologies are currently manufactured through subcontracting arrangements at the Athlone Facility, which we previously owned and sold to Novo in May 2024. Any interruption or delay in supply from the Athlone Facility, whether resulting from issues with equipment, materials, personnel, manufacturing processes, or internal or external quality audits or reviews, or issues related to the subcontracting arrangements under which these products are manufactured, could result in delays in meeting our contractual obligations and could damage our reputation and relationships with our licensees, and result in potential loss of revenues.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Tax Cuts and Jobs Act amended Section 174 of the Code (“Section 174”) and, with effect from January 2022, eliminated the option to deduct R&D expenses in the year incurred and instead requires taxpayers to capitalize, and subsequently amortize such expenses over five years for research activities conducted in the U.S., and over fifteen years for research activities conducted outside of the U.S. As such, we expect a material decrease in cash flows provided from operations and a material increase in our net U.S. deferred tax assets over the next number of years, which could have a material adverse effect on our business, financial condition, cash flows and results of operations.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedRisk Factors
limited by the terms of new share issuance authorities approved by our shareholders, our ability to use our authorized but unissued share capital to effect or to fund acquisition or other transaction opportunities, or to otherwise raise capital, could be adversely affected.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RewordedRisk Factors
And in July 2019, in order to resolve an IPR instituted by Amneal with the PTAB, we entered into a settlement and license agreement with Amneal, pursuant to which we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the latest to expire patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning sometime in 2027 2028 or earlier under certain circumstances. circumstances, and later entered into the AG Agreement with Amneal, pursuant to which we granted Amneal certain rights to distribute and sell in the U.S. an authorized generic version of VIVITROL for a one-year term beginning on the date of a Third Party ANDA Product Launch (as defined in the AG Agreement), subject to certain conditions set forth in the AG Agreement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, generic versions of certain of these products are currently subject to ANDA litigation proceedings to which we are not a party and, if such proceedings are not resolved favorably or are settled by our licensees, generic versions of these products have been launched, and others could be launched in the future, and there has been, and may be an in the future be, adverse impact impacts on the commercialization of these products and therefore on the revenue that we receive from sales of these products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Each of our facilities operates in accordance with a comprehensive quality management system, which includes risk assessment, preventive actions and regular review of inventory levels for each of the marketed products that we manufacture; however, the FDA may not consider our risk management program to be sufficient upon inspection and we may still experience shortages in the supply of marketed products that we manufacture or that are manufactured on our behalf by third parties, which could materially adversely affect the patients who rely on such marketed products and our business, financial condition, cash flows and results of operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Due For example, LUMRYZ is manufactured by a number of third-party contract manufacturers on which we rely and, due to regulatory and technical requirements, we have limited ability to shift production within our facility or to outsource any portions of our manufacturing to third parties alternative contract manufacturers in the event of an interruption in manufacturing or demand for manufacturing that exceeds our such contract manufacturers’ capacity.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Pricing and reimbursement for our products may be adversely affected by a number of factors, including: changes in, and implementation of, federal or state government regulations regulations, legislation or private third-party payors’ reimbursement policies; pressure by employers on private health insurance plans to reduce costs; and consolidation and increasing assertiveness of payors and pharmacy benefit managers (“PBMs”) seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any need to transition our manufacturing processes, or portions thereof, to a third party, whether due to an interruption in our manufacturing or due to demand for a product that exceeds our manufacturing capacity or otherwise, could take a significant amount of time and resources, may not be successful, and could cause significant interruption or delay in our ability to supply products. LUMRYZ.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, if any of our Our products or components of our products in the U.S. that are scheduled by the DEA as controlled substances, we would also be substances make us subject to DEA the DEA’s regulations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, disruptions at the FDA and other regulatory agencies that are unrelated to our company or our products, including those relating to a prolonged U.S. government shutdown, such as the one that occurred in the fall of 2025, significant changes in FDA leadership or personnel, or other global, political or economic conditions, conditions or circumstances, could cause delays to the regulatory approval process for our products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, we have received a subpoena and civil investigative demands from U.S. federal and state and federal authorities for documents related to VIVITROL, and have cooperated cooperated, or are cooperating, with the government in each instance.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
There is a risk that the we or our employees may use of social media and AI by us or our employees to communicate about our products or business or for other business purposes that may cause us to be found in violation of applicable requirements and could result in regulatory actions or legal claims against us us, including claims related to off-label marketing or other prohibited activities.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, we may not be able to successfully complete any additional transactions in the future, as such transactions are often highly competitive, and many other companies may pursue the same or similar assets to those that we may consider attractive.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market—Cardinal Health Inc., Cencora, and McKesson Corp—in the distribution of the products that we market ARISTADA and sell in the U.S. ARISTADA INITIO, LYBALVI and VIVITROL.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our Any failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue, results of operations, financial condition and cash flows.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, Teva entities filed an ANDA seeking approval to engage in the commercial manufacture, use or sale of a generic version of VIVITROL and alleged that one of our Orange-Book patents related to VIVITROL is was invalid, unenforceable and/or will would not be infringed by Teva’s proposed product.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may be subject to numerous and varying privacy and security laws, and our any failure to comply could result in penalties and reputational damage.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we entered into the Transaction Agreement with Avadel, which was subsequently amended in November 2025, pursuant to which we agreed to acquire the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per Avadel Share, payable in cash at closing and (ii) a non-transferable CVR entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone. On February 12, 2026, we successfully completed the Avadel Acquisition, adding both LUMRYZ to our portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy. During the three months ended December 31, 2025, we incurred costs of approximately $10.0 million in connection with the Avadel Acquisition.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we and our licensees have previously and may in the future face claims against IP rights covering our products and competition from generic drug manufacturers”.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in Other manufacturing and royalty revenue was primarily due to a $36.6 million decrease in revenue from FAMPYRA, as our manufacturing obligations for FAMPYRA concluded on December 31, 2024, and a $10.5 million decrease in manufacturing revenue from certain of our other legacy products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Year Ended December 31, (In millions) 2025 2024 Change External R&D expenses: Development programs: Alixorexton $ 95.8 $ 46.0 $ 49.8 LYBALVI 18.8 18.7 0.1 Other external R&D expenses 52.7 36.6 16.1 Total external R&D expenses 167.3 101.3 66.0 Internal R&D expenses: Employee-related 126.0 114.5 11.5 Occupancy 13.0 11.2 1.8 Depreciation 5.6 5.7 (0.1) Other 12.1 12.6 (0.5) Total internal R&D expenses 156.7 144.0 12.7 Research and development expenses $ 324.0 $ 245.3 $ 78.7
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
The increase in employee-related expenses was primarily due to increases in labor and benefits expense related to a 7% increase in R&D-related headcount during 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
On February 12, 2026, in connection with the Avadel Acquisition, we entered into a credit agreement (the “Credit Agreement”), by and among Alkermes plc, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto. The Credit Agreement provides for (i) a senior secured term loan A facility in an aggregate principal amount of up to $750.0 million (the “TLA Facility”) and (ii) a senior secured term loan B facility in an aggregate principal amount of up to $775.0 million (the “TLB Facility” and together with the TLA Facility, the “Facilities”). The TLA Facility matures on February 12, 2031, and the TLB Facility matures on August 12, 2031. On the closing date of the Facilities (the “Closing Date”), we borrowed the full $1.525 billion available under the Facilities.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Borrowings under the TLA Facility will bear interest at an annual rate of, at our option, either (i) the Term SOFR Rate (as defined in the Credit Agreement) plus a Secured Net Leverage Ratio (as defined in the Credit Agreement)-based margin, which will initially be 2.75% per annum or (ii) the Alternate Base Rate (as defined in the Credit Agreement) plus a Secured Net Leverage Ratio-based margin, which will initially be 1.75% per annum. Borrowings under the TLB Facility will bear interest at an annual rate of, at our option, either (i) the Term SOFR Rate plus a margin of 2.75% per annum or (ii) the Alternate Base Rate plus a margin of 1.75% per annum. We have agreed to pay certain fees and expenses in connection with the Facilities, as set forth in the Credit Agreement and certain related fee letters.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
The Credit Agreement (other than with respect to the TLB Facility) requires the maintenance of a maximum Secured Net Leverage Ratio and a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement), in each case, with the levels set forth in the Credit Agreement, as of the last day of any of our fiscal quarters ending after the Closing Date. In addition, the Credit Agreement contains customary affirmative and negative covenants that apply after the Closing Date, including limitations on indebtedness, liens, mergers, consolidations, sales of assets, investments, transactions with affiliates, restricted payments and sales and leasebacks. The Credit Agreement also contains certain customary events of default, including upon a change of control.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
The Credit Agreement is guaranteed by subsidiary guarantors and secured by a lien on substantially all of the assets of the borrowers and the subsidiary guarantors, whether owned as of the Closing Date or thereafter acquired.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Also on February 12, 2026, in connection with completion of the Avadel Acquisition and our entry into the Credit Agreement, we terminated the Bridge Credit Agreement entered into in order to fund the Avadel Acquisition, as the commitments under the Credit Agreement, together with our cash on hand, were sufficient to fund the Avadel Acquisition.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
As a result of the Separation, the historical results of our former oncology business have been reflected as discontinued operations in our consolidated financial statements through November 15, 2023, the date of the Separation. Prior period results of operations and balance sheet information have been recast to reflect this presentation.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in royalty revenues related to the long-acting INVEGA products was primarily due to the receipt in June 2023 of back royalties of $195.4 million, inclusive of $8.1 million in late-payment interest, related to 2022 U.S. sales of the long-acting INVEGA products following the successful outcome of the arbitration proceedings related to such products and the expiration of our royalty on U.S. net sales of INVEGA SUSTENNA in August 2024. Pursuant to the Final Award issued in the arbitration proceedings,
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
During the years ended December 31, 2024 and 2023, we recognized $36.6 million and $49.9 million, respectively, in manufacturing and royalty revenue related to FAMPYRA which is included within “Other” in the table above. As of December 31, 2024, our manufacturing obligations related to FAMPYRA concluded. Accordingly, we do not expect to recognize any revenues related to FAMPYRA going forward.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
Our amortizable intangible assets primarily consisted of technology and collaborative arrangements acquired as part of the acquisition of Elan Drug Technologies (“EDT”) in September 2011. These intangible assets were amortized over 12 to 13 years using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract, and became fully amortized during 2024.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
The increase in other income (expense), net was primarily due to the gain on the sale of the Athlone Facility of approximately $1.5 million, following the completion of the sale in May 2024.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. (“Rodin”) in November 2019, each of which are subject to a $0.5 million annual limitation.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
We evaluate goodwill for impairment for our reporting units annually, as of October 31, and whenever events or changes in circumstances indicate the carrying value of the reporting units may not be recoverable. A reporting unit is an operating segment, as defined by GAAP, or a component of an operating segment. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and is reviewed by management. Two or more components of an operating segment may be aggregated and deemed a single reporting unit for goodwill impairment testing purposes if the components have similar economic characteristics. As of December 31, 2024, we have one operating segment and two reporting units. Our goodwill, which solely relates to the Business Combination, has been assigned to one reporting unit which consists of the former EDT business.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
We have the option to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. If we elect this option and determine, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Among other relevant events and circumstances that affect the fair value of reporting units, we consider individual factors, such as microeconomic conditions, changes in the industry and the markets in which we operate as well as historical and expected future financial performance. Alternatively, we may elect to not first assess qualitative factors and instead immediately perform the quantitative impairment test.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RemovedMD&A
On October 31, 2024, we elected to perform a qualitative impairment test and determined that, based on the weight of all available evidence, the fair value of the reporting unit more-likely-than-not exceeded its carrying value.
Read it in 10-K Feb 12, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in expenses related to ALKS 2680 alixorexton was primarily due to an increase in increased spend related to the advancement of the development programs program for the product, including initiation of our Vibrance-3 phase 2 clinical study, costs related to the completion of our phase 1b proof-of-concept studies, initiation of our phase 2 clinical studies, Vibrance-1 and Vibrance-2 and preparatory spend in advance of initiation of phase 2 studies, startup costs related to planning for our phase 2 3 clinical program and costs related to our long-term extension study for IH. the product.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (In millions) 2025 2024 2023 Cash Cash, cash equivalents and cash equivalents, restricted cash, beginning of period $ 291.1 $ 457.5 $ 292.5 Cash flows provided by operating activities 520.8 439.1 401.4 Cash flows provided by (used in) investing activities 295.5 (111.3) Cash flows provided by investing activities (111.3) 53.3 Cash flows used in (used in) financing activities 12.4 (494.1) (289.7) Cash Cash, cash equivalents and cash equivalents, restricted cash, end of period $ 1,119.8 $ 291.2 $ 457.5
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This decrease was These decreases were partially offset by an increase in the cost of goods sold for certain of our proprietary products LYBALVI due to increases an increase in the number of units sold sold, as discussed above, and an increase in costs related to VIVITROL out-of-specification batches and subsequent investigation costs. above.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The latest to expire of our patents covering ARISTADA, ARISTADA INITIO and LYBALVI in the U.S. will expire in 2039, 2039 and 2041, respectively; and, as such, we do not anticipate any generic versions of these products to enter the market in the near term. 2041.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This decrease was partially offset by an increase We also had decreases in the cost of goods sold for certain of our proprietary products products, primarily due to increases in the number of units sold as discussed above, and an increase decreases in costs related to VIVITROL out-of-specification batches and subsequent investigation costs.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in revenue from related to RISPERDAL CONSTA was primarily due to a $3.6 million decrease of $13.0 million in manufacturing revenue, which was primarily due to a decrease in the number of batches made available to Janssen. Janssen for sale in the U.S., which has a higher selling price than product sold outside of the U.S.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Our The increase in the effective tax rate during the year ended December 31, 2024 was 16.1%, which exceeds the Irish statutory tax rate of 12.5%, primarily due to non-deductible expenses and an increase in income that was taxable at rates higher than the Irish statutory tax rate.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Included within these loss and credit carryforwards are $14.1 $13.6 million of U.S. federal NOL carryforwards and $5.8 $5.3 million of state NOL carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. in November 2019, each of which are subject to a $0.5 million annual limitation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in the cost of goods manufactured and sold was primarily due related to lower a $43.7 million decrease in the cost of goods manufactured for certain legacy products due to a decrease following the sale of the Athlone Facility in volumes of such products. May 2024.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We expect VIVITROL, ARISTADA, ARISTADA INITIO, LYBALVI LYBALVI, VIVITROL and VUMERITY VUMERITY, and our new product, LUMRYZ, which we acquired and began to market and sell in the U.S. in February 2026, to generate significant revenues for us in the near- and medium-term as we believe these products are singular or competitively advantaged products in their classes.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash flows provided by operating activities during 2024 2025 primarily consisted of net income of $367.1 $241.7 million, adjusted for non-cash items, including share-based compensation of $96.6 million and $98.7 million, depreciation and amortization of $28.5 million and $27.2 million, deferred income taxes of $40.5 million. $28.8 million and $119.1 million of changes in working capital.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in other external R&D expenses was primarily due to identifying cost-effective resourcing options for clinical programming and outsourced data management services and decreases in spend on activities associated with certain of our research preclinical development programs.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new